BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22111823)

  • 1. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
    Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
    Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
    Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
    Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
    Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
    JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management options for cast nephropathy in multiple myeloma.
    Cockwell P; Hutchison CA
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
    J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
    Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute kidney injury with cast nephropathy.
    Walther C; Podoll AS; Finkel KW
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.
    Dahal K; Shastri S; Narayanasami U; Bijol V; Rider K; Strom JA; Jaber BL
    Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
    Bridoux F; Fermand JP
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy.
    Mehta S; Shtaynberg N; Goldman M; Asti D; Kiroycheva M; Pepe J
    Hematology; 2012 Jul; 17(4):229-31. PubMed ID: 22889516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
    Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.
    Curti A; Schwarz A; Trachsler J; Tomonaga Y; Ambühl PM
    PLoS One; 2016; 11(7):e0159942. PubMed ID: 27467401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney.
    Basnayake K; Cheung CK; Sheaff M; Fuggle W; Kamel D; Nakoinz S; Hutchison CA; Cook M; Stoves J; Bradwell AR; Cockwell P
    J Clin Pathol; 2010 Oct; 63(10):884-7. PubMed ID: 20876319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
    Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
    PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.
    Hutchison CA; Bradwell AR; Cook M; Basnayake K; Basu S; Harding S; Hattersley J; Evans ND; Chappel MJ; Sampson P; Foggensteiner L; Adu D; Cockwell P
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):745-54. PubMed ID: 19339414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
    Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
    Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.